Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 3/20 | 0.51 |
| ▸ | CPA1 | P15085 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589028 | 0.87 | CYP1A2 (0.70) | CYP1A2CPA3CPA1FOLH1SLC1A3 | |
| SCHEMBL13771465 | 0.86 | CPB2 (0.56) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL5052372 | 0.86 | CYP1A2 (0.68) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL7908771 | 0.85 | CYP1A2 (0.57) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL7907545 | 0.85 | CYP1A2 (0.57) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL27417767 | 0.85 | CYP1A2 (0.57) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL4020655 | 0.85 | CYP1A2 (0.57) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL19532713 | 0.85 | CYP1A2 (0.61) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL6609906 | 0.85 | CYP1A2 (0.61) | CYP1A2EPHX1CPA3CPA1FOLH1 | |
| SCHEMBL7353741 | 0.85 | CYP1A2 (0.61) | CYP1A2EPHX1CPA3CPA1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | CYP1A2 31/4885EPHX1 1788/4885CPA3 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.